Jade Biosciences, Inc.

Jade Biosciences, Inc. Annual Report: Your Comprehensive Investor Overview

Discover the latest insights into Jade Biosciences' performance, strategy, and risks with this clear summary of their annual report for the fiscal year ended December 31, 2025. This overview provides a complete picture, helping you understand what it means for your investment in the clinical-stage biotechnology company, which trades on The Nasdaq Capital Market under the ticker symbol JBIO.

Company Profile & Key Highlights

Jade Biosciences is a clinical-stage biotechnology company focused on developing innovative therapeutic solutions for rare neurological disorders. Its primary goal is to advance JB-101, its lead drug candidate, currently in Phase 2 clinical trials for Huntington's disease.

As an "emerging growth company" and a "smaller reporting company," Jade Biosciences benefits from reduced public reporting requirements. While this can streamline operations, it also means less extensive disclosure compared to larger, established firms. This status often signals significant growth potential alongside higher inherent risks.

Key figures as of the reporting dates:

• Market Value (non-affiliates): Approximately $289.4 million as of June 30, 2025.
• Shares Outstanding: 49,316,287 shares of common stock as of February 28, 2026.

Jade Biosciences consistently complies with SEC filing requirements, submitting all necessary reports on time. The company also proactively adopted new accounting standards without using an extended transition period, demonstrating its commitment to timely financial reporting.

As a smaller reporting company, Jade Biosciences is not yet required to provide an auditor's report on the effectiveness of its internal financial controls under Sarbanes-Oxley Act Section 404(b). This means investors primarily rely on management's assessment of internal controls. Importantly, Jade Biosciences operates with real assets and operations; it is not a "shell company."

Business Overview

Jade Biosciences is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing novel therapeutics for rare neurological disorders with significant unmet medical needs. Its lead product candidate, JB-101, is an investigational small molecule currently in Phase 2 clinical development for Huntington's disease. The company uses its proprietary platform to identify and optimize drug candidates that target specific neurodegeneration pathways. Jade Biosciences' business model focuses on advancing promising drug candidates through clinical trials, with future strategies including seeking regulatory approvals, commercialization, or out-licensing.

Financial Performance for Fiscal Year 2025

Fiscal year 2025 saw Jade Biosciences significantly invest in research and development, advancing its clinical programs.

• Revenue: The company generated $5.2 million in revenue, primarily from research grants and strategic collaborations. This marks a substantial 150% increase from the previous fiscal year, reflecting growing external validation and support for its scientific efforts.
• Net Loss: Jade Biosciences reported a net loss of $35.8 million for the year, up from $28.1 million in the prior year. This widening loss resulted from intensified R&D activities, which is typical for a clinical-stage biotech company heavily investing in drug development before product commercialization and revenue generation.
• Cash Position: As of December 31, 2025, the company held $65.4 million in cash and cash equivalents. With an average quarterly cash burn rate of approximately $10 million, this cash balance provides an estimated runway of about six quarters at current spending levels, assuming no new revenue streams or financing.
• Research & Development (R&D) Expenses: R&D expenses were the largest component of operating costs, totaling $28.0 million, a 25% increase year-over-year. This demonstrates the company's commitment to advancing JB-101 through clinical trials and exploring new therapeutic avenues.

Management Discussion (MD&A Highlights)

Management attributed the increased net loss in fiscal year 2025 primarily to a substantial rise in research and development expenses. This increase stemmed from JB-101's progression into later-stage clinical trials and higher personnel costs as the company expanded its scientific team.

The 150% increase in revenue from grants and collaborations was highlighted as a positive sign of external validation for Jade Biosciences' scientific programs. Management emphasized that the current $65.4 million cash position provides an estimated operational runway of about six quarters, based on current spending rates. They acknowledged the need for future capital to complete clinical development and pursue commercialization. Management also reviewed critical accounting policies, such as revenue recognition and research and development expense capitalization, which are detailed in the notes to the financial statements.

Financial Health

As of December 31, 2025, Jade Biosciences held $65.4 million in cash and cash equivalents, its primary source of liquidity. With an average quarterly cash burn rate of approximately $10 million, the company projects a cash runway of about six quarters.

Jade Biosciences reports minimal long-term debt, primarily funding its operations and R&D activities through equity financing and grants. Current liabilities mainly consist of accounts payable and accrued expenses from ongoing clinical trials and operations. Management anticipates needing additional capital to fund operations beyond the current cash runway, underscoring the importance of future financing activities.

Future Outlook

Jade Biosciences' core strategy centers on the successful development and commercialization of JB-101. Key strategic initiatives for the upcoming year include:

• Advancing JB-101: The primary goal is to successfully complete Phase 2 clinical trials for JB-101 and, if results are positive, begin planning for Phase 3 trials. This requires continued investment in clinical operations, data analysis, and regulatory interactions.
• Pipeline Expansion: The company actively explores preclinical candidates for other rare neurological conditions. This aims to diversify its pipeline beyond JB-101 and build a sustainable long-term growth platform.
• Strategic Partnerships: Jade Biosciences continues to seek strategic partnerships and collaborations. These could accelerate development, share costs, expand market reach, and mitigate financial risks for its programs, including potential licensing agreements or co-development opportunities.
• Operational Efficiency: The company will continue to manage operating expenses while prioritizing critical R&D activities to maximize its current cash runway.

Competitive Position

The rare neurological disorder market is highly competitive and rapidly evolving. Jade Biosciences competes with larger pharmaceutical companies, established biotechnology firms, and other clinical-stage companies developing or commercializing treatments for Huntington's disease and other neurological conditions.

Key competitive factors include:

• The efficacy, safety, and tolerability of product candidates.
• The timing of market entry.
• The availability of intellectual property protection.
• The ability to recruit patients for clinical trials.

While JB-101 targets a specific mechanism of action for Huntington's disease, the company recognizes that competitors may possess greater financial, technical, and human resources. Jade Biosciences aims to differentiate itself through JB-101's unique therapeutic profile and its focused expertise in rare neurological disorders. The company relies on its intellectual property portfolio, including patents and regulatory exclusivities, to protect its product candidates.

Key Risks for Investors

Investing in Jade Biosciences involves several risks inherent to clinical-stage biotechnology companies:

• Clinical Trial Success: JB-101's success is not guaranteed. Clinical trials are lengthy, expensive, and often fail, even after promising early results. Any setbacks could significantly delay or halt development.
• Regulatory Approval: Even with successful trials, obtaining regulatory approval from bodies like the FDA is a complex, lengthy, and uncertain process. There is no guarantee that JB-101 or any future product candidates will receive necessary approvals.
• Funding Needs: Given its current cash burn and the high cost of drug development, Jade Biosciences will likely require significant additional capital in the future to complete clinical trials and commercialize any approved products. This could come from equity offerings, debt, or partnerships, potentially diluting existing shareholders or imposing restrictive covenants.
• Competition: The rare neurological disorder market is competitive. Larger pharmaceutical companies and other biotechs are also developing treatments. Competitors may develop superior products or achieve market approval more quickly.
• Market Acceptance: Even with regulatory approval, there is no guarantee of market acceptance or commercial success for their products. Factors like pricing, reimbursement, and physician adoption can influence this.
• Intellectual Property: The company's success depends on its ability to obtain, maintain, and enforce patent and other intellectual property protection for its product candidates. Failure to do so could adversely affect its competitive position.

This summary provides a snapshot of Jade Biosciences' current standing and future trajectory, emphasizing the critical information investors need to consider for their decision-making.